Back to news
Poster
Fri. 1 July

In vitro pharmacological profile of Compound A

Share on

In vitro pharmacological profile of Compound A, a novel potent and selective LRRK2 inhibitor

Authors

Pascal Grondin, Arnaud François, Anne-Pascale Luzy, Cedric Vinson, Yann Lamotte, Petra Blom, Arnaud Le Tiran, Laurence Danober, Johannes Krupp, Jan Hoflack and Nicolas Ancellin

Objectives

Strong genetic evidence has validated Leucine-Rich Repeat Kinase 2 (LRRK2) as a target of interest for Parkinson’s Disease, leading to the development of LRRK2 inhibitors as potential therapeutic approach. Among them, Compound A has recently been selected as a potent and selective LRRK2 inhibitor. This poster presents the in vitro pharmacological profile of Compound A.

 

Prepared in collaboration with Servier

 

Please see the accompanying poster for the In vivo PK/PD profile of Compound A

Read the others news

Financial
Press Release
Wed. 28 September
Oncodesign and OPM announce that Euronext Paris S.A. has authorised the admission to listing on Euronext Access+ market...

Subscribe to the OPM newsletter

Subscribe to the newsletter to not miss any news!